

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5443867/publications.pdf>

Version: 2024-02-01

81
papers

9,551
citations

76196

40
h-index

71532

76
g-index

85
all docs

85
docs citations

85
times ranked

14755
citing authors

#	ARTICLE	IF	CITATIONS
1	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. <i>Nature Genetics</i> , 2015, 47, 505-511.	9.4	1,372
2	Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. <i>Nature Genetics</i> , 2012, 44, 694-698.	9.4	1,229
3	SDH Mutations Establish a Hypermethylator Phenotype in Paraganglioma. <i>Cancer Cell</i> , 2013, 23, 739-752.	7.7	606
4	Integrated genomic characterization of adrenocortical carcinoma. <i>Nature Genetics</i> , 2014, 46, 607-612.	9.4	560
5	Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. <i>Journal of Hepatology</i> , 2017, 67, 727-738.	1.8	525
6	Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. <i>Nature Genetics</i> , 2015, 47, 1187-1193.	9.4	387
7	DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. <i>Hepatology</i> , 2015, 61, 1945-1956.	3.6	367
8	EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. <i>Science Translational Medicine</i> , 2014, 6, 244ra91.	5.8	304
9	Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation. <i>Gastroenterology</i> , 2017, 152, 880-894.e6.	0.6	290
10	Genomic Profiling of Hepatocellular Adenomas Reveals Recurrent FRK-Activating Mutations and the Mechanisms of Malignant Transformation. <i>Cancer Cell</i> , 2014, 25, 428-441.	7.7	240
11	Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis. <i>Nature Communications</i> , 2017, 8, 1315.	5.8	228
12	Genotype-phenotype correlation of CTNNB1 mutations reveals different Wnt activity associated with liver tumor progression. <i>Hepatology</i> , 2016, 64, 2047-2061.	3.6	222
13	SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. <i>International Journal of Cancer</i> , 2014, 135, 2711-2720.	2.3	155
14	Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. <i>Nature Communications</i> , 2015, 6, 6044.	5.8	153
15	Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response. <i>Gastroenterology</i> , 2019, 157, 760-776.	0.6	141
16	Mutational signature analysis identifies MUTH1 deficiency in colorectal cancers and adrenocortical carcinomas. <i>Journal of Pathology</i> , 2017, 242, 10-15.	2.1	130
17	Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma. <i>Hepatology</i> , 2020, 71, 164-182.	3.6	129
18	Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. <i>Human Molecular Genetics</i> , 2012, 21, 5397-5405.	1.4	126

#	ARTICLE	IF	CITATIONS
19	Oncometabolites-driven tumorigenesis: From genetics to targeted therapy. <i>International Journal of Cancer</i> , 2014, 135, 2237-2248.	2.3	119
20	Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress. <i>Nature Communications</i> , 2018, 9, 5235.	5.8	118
21	Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma. <i>Gut</i> , 2022, 71, 616-626.	6.1	106
22	Germline Mutations in the Mitochondrial 2-Oxoglutarate/Malate Carrier <i>SLC25A11</i> Gene Confer a Predisposition to Metastatic Paragangliomas. <i>Cancer Research</i> , 2018, 78, 1914-1922.	0.4	96
23	<i>CDKN2A</i> homozygous deletion is associated with muscle invasion in <i>FGFR3</i> -mutated urothelial bladder carcinoma. <i>Journal of Pathology</i> , 2012, 227, 315-324.	2.1	90
24	Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study. <i>Gastroenterology</i> , 2018, 155, 431-442.e10.	0.6	81
25	Adeno-associated virus in the liver: natural history and consequences in tumour development. <i>Gut</i> , 2020, 69, 737-747.	6.1	78
26	A β -Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease. <i>Hepatology</i> , 2019, 70, 231-240.	3.6	75
27	Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas. <i>Nature Communications</i> , 2016, 7, 11263.	5.8	73
28	Transethnic, Genome-Wide Analysis Reveals Immune-Related Risk Alleles and Phenotypic Correlates in Pediatric Steroid-Sensitive Nephrotic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2000-2013.	3.0	72
29	PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases. <i>International Journal of Cancer</i> , 2019, 144, 533-544.	2.3	72
30	Modular α -Helical Mimetics with Antiviral Activity against Respiratory Syncytial Virus. <i>Journal of the American Chemical Society</i> , 2006, 128, 13284-13289.	6.6	70
31	Recurrent inactivating mutations of <i>ARID2</i> in non-small cell lung carcinoma. <i>International Journal of Cancer</i> , 2013, 132, 2217-2221.	2.3	70
32	Unsuspected task for an old team: Succinate, fumarate and other Krebs cycle acids in metabolic remodeling. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2014, 1837, 1330-1337.	0.5	66
33	Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression. <i>Neuro-Oncology</i> , 2014, 16, 662-670.	0.6	59
34	DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers. <i>Clinical Cancer Research</i> , 2015, 21, 3020-3030.	3.2	53
35	Palimpsest: an R package for studying mutational and structural variant signatures along clonal evolution in cancer. <i>Bioinformatics</i> , 2018, 34, 3380-3381.	1.8	53
36	Deciphering the molecular basis of invasiveness in <i>Sdhb</i> -deficient cells. <i>Oncotarget</i> , 2015, 6, 32955-32965.	0.8	52

#	ARTICLE	IF	CITATIONS
37	Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients. <i>American Heart Journal</i> , 2018, 198, 4-17.	1.2	49
38	TET-Mediated Hypermethylation Primes SDH-Deficient Cells for HIF2 α -Driven Mesenchymal Transition. <i>Cell Reports</i> , 2020, 30, 4551-4566.e7.	2.9	49
39	A high-risk retinoblastoma subtype with stemness features, dedifferentiated cone states and neuronal/ganglion cell gene expression. <i>Nature Communications</i> , 2021, 12, 5578.	5.8	45
40	Analysis of the copy number profiles of several tumor samples from the same patient reveals the successive steps in tumorigenesis. <i>Genome Biology</i> , 2010, 11, R76.	13.9	44
41	H3K27me3 conditions chemotolerance in triple-negative breast cancer. <i>Nature Genetics</i> , 2022, 54, 459-468.	9.4	44
42	Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas. <i>Hepatology</i> , 2018, 68, 964-976.	3.6	43
43	TCF12 is mutated in anaplastic oligodendroglioma. <i>Nature Communications</i> , 2015, 6, 7207.	5.8	42
44	SNP Array Profiling of Childhood Adrenocortical Tumors Reveals Distinct Pathways of Tumorigenesis and Highlights Candidate Driver Genes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E1284-E1293.	1.8	41
45	Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer. <i>Cancer Discovery</i> , 2021, 11, 2524-2543.	7.7	41
46	XAF1 as a modifier of p53 function and cancer susceptibility. <i>Science Advances</i> , 2020, 6, eaba3231.	4.7	37
47	Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study. <i>Lancet Oncology</i> , The, 2022, 23, 161-171.	5.1	36
48	Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia. <i>Nature Communications</i> , 2018, 9, 2047.	5.8	35
49	Wild-type AAV Insertions in Hepatocellular Carcinoma Do Not Inform Debate Over Genotoxicity Risk of Vectorized AAV. <i>Molecular Therapy</i> , 2016, 24, 660-661.	3.7	33
50	Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication. <i>Hepatology</i> , 2018, 68, 1245-1259.	3.6	33
51	Germline and somatic DICER1 mutations in familial and sporadic liver tumors. <i>Journal of Hepatology</i> , 2017, 66, 734-742.	1.8	31
52	<i>APC</i> germline hepatoblastomas demonstrate cisplatin-induced intratumor tertiary lymphoid structures. <i>Oncoimmunology</i> , 2019, 8, e1583547.	2.1	31
53	Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma. <i>Genome Medicine</i> , 2021, 13, 113.	3.6	31
54	KDM1A inactivation causes hereditary food-dependent Cushing syndrome. <i>Genetics in Medicine</i> , 2022, 24, 374-383.	1.1	27

#	ARTICLE	IF	CITATIONS
55	Loss of SDHB Promotes Dysregulated Iron Homeostasis, Oxidative Stress, and Sensitivity to Ascorbate. <i>Cancer Research</i> , 2021, 81, 3480-3494.	0.4	26
56	Hypermethylator Phenotype and Ectopic GIP Receptor in GNAS Mutation-Negative Somatotropinomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1777-1787.	1.8	25
57	Mutational Processes in Hepatocellular Carcinoma: The Story of Aristolochic Acid. <i>Seminars in Liver Disease</i> , 2019, 39, 334-340.	1.8	24
58	HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients. <i>Kidney International</i> , 2021, 99, 671-685.	2.6	24
59	Deletion of Chromosomes 13q and 14q Is a Common Feature of Tumors with BRCA2 Mutations. <i>PLoS ONE</i> , 2012, 7, e52079.	1.1	20
60	DNA Methylation Signatures Reveal the Diversity of Processes Remodeling Hepatocellular Carcinoma Methylomes. <i>Hepatology</i> , 2021, 74, 816-834.	3.6	20
61	Recurrent chromosomal rearrangements of <i>ROS1</i> , <i>FRK</i> and <i>IL6</i> activating JAK/STAT pathway in inflammatory hepatocellular adenomas. <i>Gut</i> , 2020, 69, 1667-1676.	6.1	17
62	Genomic and Transcriptomic Tumor Heterogeneity in Bilateral Retinoblastoma. <i>JAMA Ophthalmology</i> , 2020, 138, 569.	1.4	17
63	Bi-allelic hydroxymethylbilane synthase inactivation defines a homogenous clinico-molecular subtype of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 77, 1038-1046.	1.8	17
64	Non-virological factors are drivers of hepatocellular carcinoma in viro-suppressed hepatitis B cirrhosis: Results of ANRS CO12 CirVir cohort. <i>Journal of Viral Hepatitis</i> , 2019, 26, 384-396.	1.0	16
65	Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas. <i>Hepatology</i> , 2022, 75, 997-1011.	3.6	16
66	Systemic AA Amyloidosis Caused by Inflammatory Hepatocellular Adenoma. <i>New England Journal of Medicine</i> , 2018, 379, 1178-1180.	13.9	15
67	Identity by Descent Mapping of Founder Mutations in Cancer Using High-Resolution Tumor SNP Data. <i>PLoS ONE</i> , 2012, 7, e35897.	1.1	8
68	AAV2 and Hepatocellular Carcinoma. <i>Human Gene Therapy</i> , 2016, 27, 211-213.	1.4	8
69	Characterization of the transcriptional and metabolic responses of pediatric high grade gliomas to mTOR-HIF-1 α axis inhibition. <i>Oncotarget</i> , 2017, 8, 71597-71617.	0.8	8
70	Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancers. <i>Lung Cancer</i> , 2022, 167, 98-106.	0.9	6
71	Combined tumor genomic profiling and exome sequencing in a breast cancer family implicates <i>ATM</i> in tumorigenesis: A proof of principle study. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 788-799.	1.5	5
72	aCNViewer: Comprehensive genome-wide visualization of absolute copy number and copy neutral variations. <i>PLoS ONE</i> , 2017, 12, e0189334.	1.1	5

#	ARTICLE	IF	CITATIONS
73	Analysis of the copy number profiles of several tumor samples from the same patient reveals the successive steps in tumorigenesis. <i>Genome Biology</i> , 2010, 11, P25.	13.9	4
74	High-resolution analysis of DNA copy number alterations in rectal cancer. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 1028-1036.	1.0	4
75	PS-047-HSD17B13 loss of function variant protects from hepatocellular carcinoma developed on alcohol related liver disease. <i>Journal of Hepatology</i> , 2019, 70, e29-e30.	1.8	1
76	Whole Exome Analysis of Relapsing Patients with Acute Promyelocytic Leukemia. <i>Blood</i> , 2016, 128, 2892-2892.	0.6	1
77	Prognostic value of chromosomal imbalances and the colon gene expression signatures in rectal cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 465-465.	0.8	0
78	Abstract 5121: Acquired inactivating ARID2 mutations in lung non small cell carcinoma. , 2012, , .		0
79	Abstract 2973: Exome sequencing of 243 liver tumors identifies new mutational signatures and potential therapeutic targets. , 2015, , .		0
80	Abstract 919: Adeno-associated virus 2 (AAV2) induces recurrent insertional mutagenesis in human hepatocellular carcinomas. , 2015, , .		0
81	Structure, Dynamics, and Impact of Replication Stressâ€œInduced Structural Variants in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2022, 82, 1470-1481.	0.4	0